78
Views
3
CrossRef citations to date
0
Altmetric
Review

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

Pages 91-101 | Published online: 30 Apr 2010

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.